Raltegravir is a topic covered in the Johns Hopkins ABX Guide.
To view the entire topic, please sign in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
FDA
- Treatment of HIV-1 infection in combination with other ARV agents in ART-experienced pts with evidence of HIV replication despite ongoing ART.
- Treatment of HIV-1 infection in combination with other ARV agents in ART-naive pts.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Substitution for other ARV agents due to drug toxicity or intolerance in pts on suppressive regimen (limited data)
-- To view the remaining sections of this topic, please sign in or purchase a subscription --
Last updated: July 11, 2014
Citation
* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Raltegravir
ID - 540471
A1 - ,,
AU - Hsu,Alice,Pharm.D.
AU - Pham,Paul,Pharm.D. BCPS
Y1 - 2014/07/11/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540471/all/Raltegravir
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -